Vasomune Therapeutics and AnGes drug candidate AV-001 receives positive recommendation from the IDSMB for AV001-004 phase 2a study

Vasomune Therapeutics, a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases associated with vascular dysfunction, recently announced that their lead drug candidate AV-001 has received positive recommendation from the Independent Data and Safety Monitoring Board (IDSMB) of the AV001-004 Phase 2a Study.

Vasomune Therapeutics is an OBIO® member and an alumnus of the CAAP® program.